Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $11.95, but opened at $11.50. Stoke Therapeutics shares last traded at $11.69, with a volume of 17,223 shares changing hands.
A number of research firms have weighed in on STOK. Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Thursday, August 8th. HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. Finally, Wedbush reissued an "outperform" rating and set a $17.00 target price on shares of Stoke Therapeutics in a research note on Thursday, July 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $21.40.
Check Out Our Latest Report on STOK
The stock has a market capitalization of $608.25 million, a P/E ratio of -4.96 and a beta of 0.97. The business has a fifty day simple moving average of $13.91 and a 200-day simple moving average of $13.68.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.11. The company had revenue of $4.83 million for the quarter, compared to the consensus estimate of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. On average, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.1 earnings per share for the current year.
In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the company's stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares of the company's stock, valued at approximately $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.30% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of the business. Quest Partners LLC bought a new position in shares of Stoke Therapeutics in the second quarter valued at $29,000. Nisa Investment Advisors LLC lifted its position in Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company's stock valued at $40,000 after acquiring an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Stoke Therapeutics in the 2nd quarter valued at about $123,000. State Board of Administration of Florida Retirement System acquired a new position in Stoke Therapeutics during the 1st quarter valued at about $141,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock worth $189,000 after purchasing an additional 1,994 shares in the last quarter.
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.